GSK (LON:GSK) Stock Crosses Above 200-Day Moving Average - Here's Why

GSK plc (LON:GSK - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,395.23 ($18.83) and traded as high as GBX 1,448 ($19.54). GSK shares last traded at GBX 1,425.50 ($19.24), with a volume of 6,218,375 shares traded.

Analyst Ratings Changes

Several equities research analysts have weighed in on GSK shares. Shore Capital restated a "buy" rating on shares of GSK in a research note on Wednesday, April 30th. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a report on Friday, March 28th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. According to data from MarketBeat, GSK presently has a consensus rating of "Moderate Buy" and a consensus target price of GBX 1,862.50 ($25.14).

GSK Stock Up 3.5%

The business's fifty day moving average price is GBX 1,396.37 and its two-hundred day moving average price is GBX 1,396.79. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The stock has a market capitalization of £61.15 billion, a PE ratio of 24.34, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported GBX 44.90 ($0.61) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. On average, equities research analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Wendy Becker bought 536 shares of the stock in a transaction on Thursday, March 20th. The shares were bought at an average price of GBX 1,515 ($20.45) per share, with a total value of £8,120.40 ($10,960.18). Also, insider Emma Walmsley sold 5,473 shares of the company's stock in a transaction dated Tuesday, May 6th. The shares were sold at an average price of GBX 1,449 ($19.56), for a total transaction of £79,303.77 ($107,037.08). 1.61% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.